128 related articles for article (PubMed ID: 28778363)
1. Kidney Toxicities Associated With Novel Cancer Therapies.
Lefebvre J; Glezerman IG
Adv Chronic Kidney Dis; 2017 Jul; 24(4):233-240. PubMed ID: 28778363
[TBL] [Abstract][Full Text] [Related]
2. Toxicities of checkpoint inhibitors: causes and management.
Postow MA
Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
[No Abstract] [Full Text] [Related]
3. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
5. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Immunotherapy: Picking a Winner.
Teng MW; Khanna R; Smyth MJ
Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
[TBL] [Abstract][Full Text] [Related]
7. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.
Kourie HR; Awada G; Awada A
Immunotherapy; 2017 Jun; 9(8):647-657. PubMed ID: 28653570
[TBL] [Abstract][Full Text] [Related]
8. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
[TBL] [Abstract][Full Text] [Related]
9. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors.
Kreamer K; Riordan D
Clin J Oncol Nurs; 2015 Dec; 19(6):734-42. PubMed ID: 26583637
[TBL] [Abstract][Full Text] [Related]
11. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
13. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
14. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
15. Renal toxicity of anticancer agents targeting HER2 and EGFR.
Cosmai L; Gallieni M; Porta C
J Nephrol; 2015 Dec; 28(6):647-57. PubMed ID: 26341657
[TBL] [Abstract][Full Text] [Related]
16. Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.
Einstein DJ; McDermott DF
Clin Adv Hematol Oncol; 2017 Jun; 15(6):478-488. PubMed ID: 28749908
[TBL] [Abstract][Full Text] [Related]
17. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role.
Eisen T
Eur J Cancer; 2015 Nov; 51(17):2578-9. PubMed ID: 26613659
[No Abstract] [Full Text] [Related]
20. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
